Search results
Showing 331 to 345 of 476 results for learning disabilities
generally or those with comorbidities, neurodevelopmental disorders, learning disabilities or different communication needs (due to...
Sarilumab for moderate to severe rheumatoid arthritis (TA485)
Evidence-based recommendations on sarilumab (Kevzara) for treating moderate to severe rheumatoid arthritis in adults.
This quality standard covers contraception for women, including emergency contraception. It describes high-quality care in priority areas for improvement.
View quality statements for QS129Show all sections
NICE has developed a medtech innovation briefing (MIB) on d-Nav insulin management app for type 2 diabetes .
This quality standard covers the prevention or delay of harmful use of drugs by children, young people and adults most likely to start using drugs, or already experimenting or using drugs occasionally. This includes illegal psychoactive substances, solvents, volatile substances, image- and performance-enhancing drugs, prescription-only medicines and over-the-counter medicines. It describes high-quality care in priority areas for improvement.
View quality statements for QS165Show all sections
Sections for QS165
- Quality statements
- Quality statement 1: Assessment of looked-after children and young people
- Quality statement 2: Assessment of care leavers
- Quality statement 3: Assessment of children and young people in contact with youth offending services
- Quality statement 4: Information and advice for adults
- Update information
- About this quality standard
Baricitinib for treating moderate to severe atopic dermatitis (TA681)
Evidence-based recommendations on baricitinib for treating moderate to severe atopic dermatitis in adults.
Certolizumab pegol for treating moderate to severe plaque psoriasis (TA574)
Evidence-based recommendations on certolizumab pegol (Cimzia) for treating moderate to severe plaque psoriasis in adults.
This guideline covers the identification, assessment and treatment of attachment difficulties in children and young people up to age 18 who are adopted from care, in special guardianship, looked after by local authorities in foster homes (including kinship foster care), residential settings and other accommodation, or on the edge of care. It aims to address the many emotional and psychological needs of children and young people in these situations, including those resulting from maltreatment.
Digital therapy for chronic tic disorders and Tourette syndrome: early value assessment (HTG748)
Early value assessment (EVA) guidance on digital therapy for chronic tic disorders and Tourette syndrome.
Osteoarthritis in over 16s: diagnosis and management (NG226)
This guideline covers the diagnosis, assessment and non-surgical management of osteoarthritis. It aims to improve management of osteoarthritis and the quality of life for people with osteoarthritis.
Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel (TA391)
Evidence-based recommendations on cabazitaxel (Jevtana) for people with prostate cancer that has come back after it was treated with docetaxel.
Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria (TA778)
Evidence-based recommendations on pegcetacoplan (Aspaveli) for treating paroxysmal nocturnal haemoglobinuria in adults who have anaemia after at least 3 months of treatment with a C5 inhibitor.
Evidence-based recommendations on aripiprazole for treating moderate to severe manic episodes in young people with bipolar I disorder.
Evidence-based recommendations on adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi) and infliximab (Remicade, Remsima, Inflectra). These drugs are for people with active ankylosing spondylitis or non-radiographic axial spondyloarthritis .
Behaviour change: digital and mobile health interventions (NG183)
This guideline covers interventions that use a digital or mobile platform to help people eat more healthily, become more active, stop smoking, reduce their alcohol intake or practise safer sex. The interventions include those delivered by text message, apps, wearable devices or the internet. The guideline only includes those that are delivered by the technology itself and not by healthcare professionals using technology to deliver interventions.